Nanotech Drug Formulations Drive Dealmaking

13 May 2014 Cleantech & Nano Publication

Some of the most commercially successful products to arise out of nanotechnology in terms of sheer size of revenues generated are nanotech drug formulations. This area continues to be hot in the wake of two recent deals, both focused on improved ways of delivering doxorubicin, a cancer therapeutic, in a delivery system.

First, NanoValent and NanoSmart announced a research collaboration on April 17th to explore the prospect of combining two separate nanotech targeting technologies in a single doxorubicine product. The combined product will feature NanoValent’s hybrid polymerized liposomal nanoparticle delivery technology and also NanoSmart’s anti-nuclear antibody platform, which targets necrosis associated with solid tumors.

Another deal was announced April 16th between BioAlliance and Topotarget, featuring another nanotech formulation of doxorubicin targeting the most common type of liver cancer. This product is in Phase III clinical trials and uses a “Trojan Horse” strategy to combat resistant tumor cells in which a polymer coating tricks the cells into allowing the polymer nanoparticles to enter with the doxorubicin payload. As part of the deal, the two companies merged together in an all-share transaction.

The first nanoparticulate drug formulation (involving the drug sirolimus) was approved by the FDA in 2000. Fourteen years later, the pipeline of nanotech drug formulations continues to grow. Some of the products work by more effectively targeting the diseased area, while others improve the solubility of a drug that is otherwise difficult to administer. The improvements resulting from these smart delivery systems may reduce the amount of drug needed, increase efficacy and/ or reduce side effects in patients.

Related Services

Insights

California Statute Offers Dramatic Change to Independent Contractor, Franchise-Franchisee Relationships
20 September 2019
Legal News: Distribution & Franchise
AI Ouch! AI Job Interview Law Starting in 2020!
20 September 2019
Internet, IT & e-Discovery Blog
RCE PTA Carve-Out Resumes After Interference
18 September 2019
PharmaPatents
The Ninth Circuit Expected to Rule that Doctors Can Be Wrong in the Winter v. Gardens False Claims Act Case
18 September 2019
Legal News: Government Enforcement Defense & Investigations
Lacktman, Ferrante Cited in mHealth Intelligence About Ryan Haight Act
19 September 2019
mHealth Intelligence
Vernaglia Comments on AHA v Azar Decision
18 September 2019
MedPage Today
Tinnen Discusses How Viewpoint Diversity Helps Businesses Thrive
18 September 2019
InsideTrack
Lach Comments on Launch of New Group
16 September 2019
BizTimes Milwaukee
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
BRG Healthcare Leadership Conference
06 December 2019
Washington, D.C.
CTeL Telehealth Fall Summit 2019
04-06 December 2019
Washington, D.C.